HK Stock Market Move | REMEGEN (09995) surged more than 17%. Core product Taietisib authorized for international market. RC148 is a hot area for business cooperation.

REMEGEN (09995) rose more than 17%, as of the time of writing, it rose by 17.47% to 69.25 Hong Kong dollars, with a trading volume of 1.489 billion Hong Kong dollars. On the news front, REMEGEN previously announced that it has granted exclusive development rights in Greater China to Vor Bio for Taitusi Pei. According to this, Vor Bio is required to pay REMEGEN and Hon Partners a total price of $125 million, including the company receiving an initial payment of $45 million from Vor Bio and Vor Bio issuing $80 million worth of warrants to Hon Partners. In addition, the company's previous annual report disclosed that a Phase II clinical study of RC148 in combination with dositacil for the treatment of advanced lung cancer is underway in China. As of December 31, 2024, the clinical trial is progressing smoothly. RC148 is REMEGEN's first clinically approved dual antibody. A Citibank research report pointed out that Taitusi Pei presented promising CN Ph3 data at the AAN2025 conference, with the potential for global myasthenia gravis (gMG) being a key focus for investors. The bank believes that the global competition in the field of global myasthenia gravis is fierce, and that consistent Ph3 research on a global scale is key to its successful global commercialization. Additionally, due to RC148 (PD-1/VEGF) being a popular area of business cooperation, it has also attracted the interest of investors.